Recently, BAP1 catalytic inhibitors have been developed that inhibit ASXL1‐driven leukaemic gene signatures and impaired tumour progression in an in vivo model of ASXL1 AML [22]. The gene discussed is BAP1; the disease is acute myeloid leukemia.